Retatrutide: The Triple Agonist GLP-1 Drug That Could Outperform Ozempic and Mounjaro

A new era in obesity medicine may be arriving sooner than most people realize. Retatrutide — developed by Eli Lilly under the research code LY3437943 — is not just another GLP-1 drug. It is the world's first triple hormone receptor agonist to reach late-stage clinical trials, simultaneously activating the GLP-1, GIP, and glucagon receptors. In Phase 3 trials, it produced an average weight loss of 28.7% — roughly 71 pounds — in 68 weeks. That approaches the territory of bariatric surgery.

This guide covers everything currently known about retatrutide: how it works, what the clinical data shows, how it compares to semaglutide and tirzepatide, its side effects, dosing protocols from trials, and the current timeline toward FDA approval.

What Is Retatrutide?

Retatrutide is a synthetic 39-amino acid peptide engineered by Eli Lilly. It was designed with a deliberate structural innovation: rather than targeting one or two hormone receptors like existing drugs, it hits three simultaneously.

• GLP-1 receptor (GLP-1R) — Stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and powerfully reduces appetite via the central nervous system.
• GIP receptor (GIPR) — Amplifies the insulin response to meals and blunts the nausea that GLP-1 receptor agonism tends to cause, enabling higher effective doses. GIP co-agonism also synergizes with GLP-1R activity on adipose tissue.
• Glucagon receptor (GCGR) — This is retatrutide's key differentiator from tirzepatide. Glucagon receptor agonism significantly increases resting energy expenditure (thermogenesis) and drives hepatic fatty acid oxidation, directly clearing fat from the liver. This additional mechanism explains why retatrutide achieves materially higher weight loss than dual agonists.

Structurally, retatrutide is built on a GIP peptide backbone with three non-coded amino acid substitutions, including Aib2 (alpha-aminoisobutyric acid at position 2) to protect it from DPP-4 enzyme degradation. This engineering enables a once-weekly subcutaneous injection schedule.

Clinical Trial Results: The Numbers

Phase 1b (2022) — Safety Established

Published in The Lancet, the Phase 1b multiple-ascending dose trial in people with type 2 diabetes established retatrutide's safety and pharmacokinetics over 12 weeks. It confirmed dose-dependent reductions in blood glucose and body weight consistent with the triple-receptor mechanism and supported progression to Phase 2.

Phase 2 Obesity Trial (NEJM, June 2023)

This was the trial that put retatrutide on the map. The randomized, double-blind, placebo-controlled study enrolled 338 adults with obesity or overweight (without diabetes) across multiple sites, running from May 2021 to November 2022.

Weight loss at 24 weeks:

• 1 mg: −7.2%
• 4 mg: −12.9%
• 8 mg: −17.3%
• 12 mg: −17.5%
• Placebo: −1.6%

Weight loss at 48 weeks:

• 1 mg: −8.7%
• 4 mg: −17.1%
• 8 mg: −22.8%
• 12 mg: −24.2% (approximately 58 lbs / 26 kg in absolute terms)
• Placebo: −2.1%

Additionally, 72% of participants who had prediabetes at baseline reverted to normoglycemia — a remarkable metabolic finding.

Phase 2 Type 2 Diabetes Trial (The Lancet, 2023)

In people with established type 2 diabetes, retatrutide reduced HbA1c significantly versus both placebo and 1.5 mg dulaglutide (an established GLP-1 agonist). Weight loss reached up to −16.9% at 36 weeks — described as the most weight loss ever reported in a T2D pharmacological trial at the time. Lipid profiles, blood pressure, and liver enzymes all improved meaningfully.

Phase 2a MASLD Trial (Nature Medicine, 2024)

This may be retatrutide's most striking finding outside of obesity. In people with metabolic dysfunction-associated steatotic liver disease (MASLD — formerly called NAFLD), the 12 mg dose reduced liver fat content by up to 86% at 48 weeks. Approximately 93% of participants on the highest dose achieved normal liver fat levels. Fibrosis markers and liver enzymes improved significantly, pointing toward a potential breakthrough treatment for a condition that affects roughly 25% of the global adult population with few currently approved therapies.

Phase 3 — TRIUMPH Program (First Results: December 2025)

Eli Lilly launched the TRIUMPH program — a suite of Phase 3 registrational trials across multiple indications. The first top-line data arrived in December 2025 from TRIUMPH-4, focused on adults with obesity and knee osteoarthritis.

TRIUMPH-4 Results (68 weeks):

• 9 mg maintenance dose: −26.4% body weight
• 12 mg maintenance dose: −28.7% body weight (average ~71 lbs / 32 kg)
• WOMAC pain score reduction: up to 4.5 points (75.8%) — highly significant arthritis pain relief
• Meaningful improvements in physical function

Six to seven additional TRIUMPH readouts are expected throughout 2026, including TRIUMPH-1, the pivotal obesity trial (no comorbidity required), anticipated in Q2–Q3 2026.

Retatrutide vs. Semaglutide vs. Tirzepatide

No direct head-to-head randomized trial has been published yet. Comparisons below are cross-trial and should be interpreted with that caveat.

The key message: retatrutide's glucagon receptor component unlocks approximately 5–8 additional percentage points of weight loss over tirzepatide, largely by increasing resting energy expenditure and driving superior hepatic fat clearance. The trade-off is a novel side effect class (dysesthesia) not seen with the other two drugs.

Side Effects and Safety Profile

Gastrointestinal (Most Common)

As a GLP-1/GIP/glucagon triple agonist, retatrutide shares the GI side effect profile common to the class: nausea, vomiting, diarrhea, and constipation. These effects are dose-dependent, predominantly occur during dose escalation, and are generally mild to moderate and transient. The GIP component helps blunt GI intolerance compared to pure GLP-1 monotherapy. Discontinuation rates due to adverse events ranged approximately 7–16% across dose arms in Phase 2.

Dysesthesia (Novel to Retatrutide)

The most notable side effect unique to retatrutide is dysesthesia — tingling, burning, or altered skin sensation. This affected approximately 20.9% of participants on 12 mg in Phase 3 data. It is believed to be linked to glucagon receptor activity and has not been observed at this rate with semaglutide or tirzepatide. In most cases it is mild-to-moderate and does not lead to discontinuation, but it is worth understanding before starting.

Cardiovascular Signals

Heart rate increases of ~5–7 bpm above baseline have been observed (dose-dependent), consistent with the glucagon receptor component. Tachycardia or irregular heartbeat signals were reported in 4–14% of retatrutide groups versus 2–3% in placebo arms in Phase 2. No increase in major adverse cardiovascular events (MACE) has been reported. Critically, blood pressure decreased significantly: 41% of participants on 8 mg were able to discontinue antihypertensive medications.

Metabolic Benefits

• Triglycerides reduced by ~40.6%
• Non-HDL cholesterol reduced by ~26.9%
• Liver enzymes improved, not elevated

Standard Class Precautions

As with all GLP-1-class drugs, personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) is a presumed contraindication. No serious hepatotoxicity or pancreatitis signals have been highlighted as distinct from the drug class overall.

Dosing Protocol (From Clinical Trials)

Retatrutide is administered as a once-weekly subcutaneous injection, following a gradual titration schedule to minimize GI side effects:

Phase 3 TRIUMPH trials are testing 4 mg, 9 mg, and 12 mg as maintenance doses. A 4 mg arm was added to identify a lower-dose option with fewer side effects. The 12 mg dose consistently shows the most weight loss; the 8–9 mg range offers a meaningful efficacy-to-tolerability balance for many patients.

Important note: Retatrutide is not approved for human use as of April 2026. The dosing above is from investigational clinical trials only and is not a prescription recommendation.

Beyond Weight Loss: Additional Benefits Being Studied

Osteoarthritis Pain

TRIUMPH-4's WOMAC pain score reduction of up to 75.8% far exceeds what would be expected from weight loss alone, suggesting direct anti-inflammatory mechanisms. Eli Lilly is pursuing a formal osteoarthritis indication.

Liver Disease (MASLD/MASH)

The Phase 2a data showing 86% liver fat reduction is among the most dramatic published for any drug in MASLD. The SYNERGY Phase 3 program is specifically targeting regulatory approval for this liver disease indication — a potential blockbuster application given the 25% global adult prevalence of MASLD and scarcity of approved treatments.

Obstructive Sleep Apnea

Following tirzepatide's successful SURMOUNT-OSA trial, a nested OSA basket within TRIUMPH is evaluating whether retatrutide reduces apnea-hypopnea index (AHI). Given the correlation between obesity, fat deposition around the airway, and OSA severity, meaningful reductions are anticipated.

Cardiovascular Risk

TRIUMPH-CVOT (~10,000 patients with established cardiovascular disease) is running on a multi-year timeline. The improvements in blood pressure, lipids, blood glucose, and body weight all point toward plausible cardiovascular benefit, but outcomes data won't be available until approximately 2029.

FDA Approval Timeline

Priority Review designation is possible given the unmet clinical need in obesity, which could accelerate the timeline by 6 months. With the TRIUMPH-4 Phase 3 data already positive, Eli Lilly has its first building block for the NDA package.

Is Retatrutide Available Now?

As of April 2026, retatrutide is not approved anywhere in the world and is not commercially available. It is only accessible through active clinical trials. Some compounding pharmacies and research chemical suppliers have marketed peptides labeled as retatrutide, but these products are unregulated, unverified, and carry significant safety and legal risks. There is currently no way to obtain pharmaceutical-grade retatrutide outside of a registered clinical trial.

To find open TRIUMPH trials and check eligibility, visit ClinicalTrials.gov and search for "retatrutide" or "LY3437943."

Conclusion

Retatrutide represents the most potent weight-loss drug to reach Phase 3 clinical trials in history. Its triple-receptor mechanism — adding glucagon receptor agonism to the GLP-1/GIP dual agonism of tirzepatide — drives meaningfully greater weight loss (~28.7% at 68 weeks), superior liver fat clearance, and increased energy expenditure. The TRIUMPH-4 Phase 3 results confirmed efficacy in obesity with comorbid knee osteoarthritis, and six-plus additional pivotal readouts are expected in 2026.

The main unknowns: long-term cardiovascular outcomes, the commercial safety profile beyond trials, muscle mass effects, and whether the novel dysesthesia side effect becomes more significant at scale. If TRIUMPH-1 succeeds as expected, an FDA NDA filing in Q4 2026 and potential approval in mid-to-late 2027 would put retatrutide in pharmacies around the same time the next generation of GLP-1 drugs is redefining what obesity medicine can achieve.

This article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug not approved for use outside of clinical trials. Consult a qualified healthcare provider before making any medical decisions.